{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:48:08Z","timestamp":1780343288740,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T00:00:00Z","timestamp":1229472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00520-008-0553-7","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T12:45:20Z","timestamp":1229431520000},"page":"719-725","source":"Crossref","is-referenced-by-count":23,"title":["Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review"],"prefix":"10.1007","volume":"17","author":[{"given":"Ingo J.","family":"Diel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"K\u00f6ppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Antr\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Wintfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Neary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,17]]},"reference":[{"key":"553_CR1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1634\/theoncologist.9-3-319","volume":"9","author":"J Berenson","year":"2004","unstructured":"Berenson J, Hirschberg R (2004) Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 9:319\u2013329","journal-title":"Oncologist"},{"key":"553_CR2","first-page":"534","volume":"29","author":"R Bergner","year":"2006","unstructured":"Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006) Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29:534\u2013540 doi: 10.1159\/000096056","journal-title":"Onkologie"},{"key":"553_CR3","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"553_CR4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133\u20131137","journal-title":"Br J Cancer"},{"key":"553_CR5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2354.2005.00641.x","volume":"15","author":"JJ Body","year":"2006","unstructured":"Body JJ, Diel IJ, Tripathy D, Bergstr\u00f6m B (2006) Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl) 15:299\u2013302","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3 Suppl.1","key":"553_CR6","first-page":"S69","volume":"38","author":"JJ Body","year":"2006","unstructured":"Body JJ, Lichinitser M, Tjulandin S, Bergstr\u00f6m B (2006) Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data [abstract 68]. Bone 38(3 Suppl.1):S69","journal-title":"Bone"},{"key":"553_CR7","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra022308","volume":"349","author":"JT Chang","year":"2003","unstructured":"Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676\u20131679","journal-title":"N Engl J Med"},{"key":"553_CR8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00520-004-0628-z","volume":"12","author":"B Chern","year":"2004","unstructured":"Chern B, Joseph D, Joshua D et al (2004) Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 12:463\u2013466","journal-title":"Support Care Cancer"},{"key":"553_CR9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460","journal-title":"Curr Med Res Opin"},{"issue":"Suppl.9","key":"553_CR10","first-page":"78","volume":"17","author":"IJ Diel","year":"2006","unstructured":"Diel IJ, Weide R, K\u00f6ppler H et al (2006) Renal impairment in cancer patients following zoledronic acid or ibandronate treatment [abstract 1002P]. Ann Oncol 17(Suppl.9):78","journal-title":"Ann Oncol"},{"key":"553_CR11","first-page":"408","volume":"72","author":"R Eastell","year":"2006","unstructured":"Eastell R, Garnero P, Vrijens B et al (2006) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408","journal-title":"Calcif Tissue Int"},{"key":"553_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","volume":"42","author":"A Ezra","year":"2000","unstructured":"Ezra A, Golomb B (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175\u2013195","journal-title":"Adv Drug Deliv Rev"},{"key":"553_CR13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR, M\u00fcller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745\u2013751","journal-title":"J Bone Miner Res"},{"issue":"Suppl.5","key":"553_CR14","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S1359-6349(03)90923-2","volume":"1","author":"A Heidenreich","year":"2003","unstructured":"Heidenreich A, Ohlmann C, Olbert P Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1(Suppl.5):S270","journal-title":"Eur J Cancer"},{"key":"553_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2004-10-4097","volume":"106","author":"D Henrich","year":"2005","unstructured":"Henrich D, Bergner R, Hoffman M et al (2005) Open-label study of ibandronate in elderly myeloma patients with pre-existing renal deterioration [abstract 3459]. Blood 106:11","journal-title":"Blood"},{"issue":"Suppl.","key":"553_CR16","first-page":"738","volume":"22","author":"KB Johnson","year":"2003","unstructured":"Johnson KB, Gable P, Kaine EM et al (2003) Significant deterioration in renal function with the new bisphosphonate zoledronic acid [abstract 2968]. J Clin Oncol 22(Suppl.):738","journal-title":"J Clin Oncol"},{"key":"553_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","volume":"246","author":"B Kristensen","year":"1999","unstructured":"Kristensen B, Ejlertsen B, Groenvold M et al (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246:67\u201364","journal-title":"J Intern Med"},{"key":"553_CR18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"553_CR19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00044011-200323110-00003","volume":"23","author":"NV Lyubimova","year":"2003","unstructured":"Lyubimova NV, Kushlinsky NE, Lichinister MR Schlosser K (2003) Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. Clin Drug Invest 23:707\u2013716","journal-title":"Clin Drug Invest"},{"key":"553_CR20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558\u2013567","journal-title":"J Clin Oncol"},{"key":"553_CR21","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","volume":"22","author":"I Mancini","year":"2004","unstructured":"Mancini I, Dumon JC Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587\u20133592","journal-title":"J Clin Oncol"},{"key":"553_CR22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281\u2013289","journal-title":"Kidney Int"},{"issue":"Suppl.","key":"553_CR23","first-page":"735","volume":"22","author":"S Mazj","year":"2004","unstructured":"Mazj S, Lichtman SM (2004) Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics [abstract 8039]. J Clin Oncol 22(Suppl.):735","journal-title":"J Clin Oncol"},{"key":"553_CR24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","volume":"6","author":"RC M\u00fchlbauer","year":"1991","unstructured":"M\u00fchlbauer RC, Bauss F, Schenk R et al (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003\u20131011","journal-title":"J Bone Miner Res"},{"key":"553_CR25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E589","volume":"39","author":"A Munier","year":"2005","unstructured":"Munier A, Gras V, Andrejak M et al (2005) Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39:1194\u20131197","journal-title":"Ann Pharmacother"},{"key":"553_CR26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0300-483X(03)00257-9","volume":"191","author":"T Pfister","year":"2003","unstructured":"Pfister T, Atzpodien E, Bauss F (2003) The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191:159\u2013167","journal-title":"Toxicology"},{"key":"553_CR27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2005.pto_160.x","volume":"97","author":"T Pfister","year":"2005","unstructured":"Pfister T, Atzpodien E, Bohrmann B, Bauss F (2005) Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 97:374\u2013381","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"553_CR28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/ciia.2006.1.4.415","volume":"1","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415\u2013423","journal-title":"Clin Interv Aging"},{"key":"553_CR29","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735\u20131744","journal-title":"Cancer"},{"key":"553_CR30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","volume":"77","author":"H Taggart","year":"2002","unstructured":"Taggart H, Bolognese MA, Lindsay R et al (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77:262\u2013270","journal-title":"Mayo Clin Proc"},{"key":"553_CR31","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199605303342207","volume":"334","author":"R Thadhani","year":"1996","unstructured":"Thadhani R, Pascual M, Bonventre JV (1996) Acute renal failure. N Engl J Med 334:1448\u20131460","journal-title":"N Engl J Med"},{"key":"553_CR32","doi-asserted-by":"crossref","unstructured":"von Moos R, Caspar CB, Angst R et al (2006) Renal safety of intravenous ibandronate 6 mg infused over 15 minutes or 60 minutes in patients with breast cancer and bone metastases [abstract 1078]","DOI":"10.1200\/jco.2007.25.18_suppl.1114"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-008-0553-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0553-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T20:42:29Z","timestamp":1589402549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-008-0553-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,17]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1007\/s00520-008-0553-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,17]]}}}